Mon, Jan 26, 2015, 4:03 AM EST - U.S. Markets open in 5 hrs 27 mins


% | $
Quotes you view appear here for quick access.

ImmunoCellular Therapeutics, Ltd. Message Board

  • techtrader79 techtrader79 Mar 7, 2013 2:04 PM Flag

    Expecting a climb into the close.

    Let's face it, IMUC has a market cap that is extremely undervalued for a one of a kind Glioblastoma vaccine that turns in 18+ months of progression free survival. That's worth at least $1 Billion in market cap. Plus their IIb trial will allow them to submit and NDA to the FDA this year. This is $14-18 stock easy.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • The only part that I disagree with is that we will not reach 64 deaths in Q4 of this year. All the officers know this; however, at this time, being blinded to the results, they cannot yet promise that much efficacy.

      • 1 Reply to discoduck33
      • Disco, I re-ran my previous projections based on all of the numbers and assumptions given in the call and the enrollment curve vs randomization and came up with a trial reaching 32 events right about end of March. I pushed it back to zero advantage and 32'd in Nov of 12. I then pushed it up to 36 months and got 32 events in June with barely enough time to get the report in q2. What I have not been able to do yet is show 64 events in 2013 (more like March of 14) and that is without any curve separation. I just don't think we be done in this year. But the hype when we're not is going to be a blast!

    • do you think we hit 14-18 by end of year ? thnx

0.68-0.0014(-0.21%)Jan 23 4:02 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.